Therapeutic advances in medical oncology · 2026
NALIRIFOX versus liposomal irinotecan plus fluorouracil/leucovorin as the second-line chemotherapy in gemcitabine refractory pancreatic adenocarcinoma: a real-world study.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wong Wei-Ze, Chiang Nai-Jung, Lee Kuei-Chuan, Yu Hung-Yuan, Tsai Chia-Jui, Hsu Shao-Jung, Lee Pei-Chang, Chen Ming-Huang, Huang Hui-Chun, Li Chung-Pin, Luo Jiing-Chyuan, Lee Fah-Yauh
Аннотация
BACKGROUND: Pancreatic adenocarcinoma has a high mortality rate. Nanoliposomal irinotecan plus 5-fluorouracil and leucovorin (nal-IRI/FL) is the standard second-line chemotherapy after gemcitabine-based therapy. Although nanoliposomal irinotecan plus oxaliplatin, fluorouracil, and leucovorin (NALIRIFOX) has shown superior efficacy as first-line therapy over gemcitabine and nab-paclitaxel, its roles as second-line therapy remains undefined.
OBJECTIVES: We aimed to compare the clinical outcomes and safety profiles of NALIRIFOX and nal-IRI/FL when used as a second-line treatment for patients with pancreatic adenocarcinoma who have progressed on a gemcitabine-based therapy.
DESIGNS: This was a single-center retrospective cohort study.
METHODS: We included patients with locally advanced or metastatic pancreatic adenocarcinoma who received NALIRIFOX or nal-IRI/FL following progression on first-line gemcitabine-based therapy from September 2020 to October 2024.
RESULTS: A total of 62 patients in the NALIRIFOX group and 131 in the nal-IRI/FL group were analyzed. Cumulative dose intensity ⩾80% over four cycles was achieved in 81.4% of the NALIRIFOX group and 73.1% of the nal-IRI/FL group (p = 0.32). The median progression-free survival (PFS) was 4.0 months (95% confidence interval (CI): 3.6-4.5) in the NALIRIFOX group versus 2.5 months (95% CI: 2.1-3.0) in the nal-IRI/FL group (hazard ratio (HR): 0.686; 95% CI: 0.497-0.947; p = 0.021), and the median overall survival was 7.0 months (95% CI: 5.0-9.1) versus 6.3 months (95% CI: 4.4-8.1), respectively (p = 0.827). Of the patients with disease progression after nal-IRI/FL, 69.1% received oxaliplatin-containing chemotherapy. Grade 3-4 adverse events were more frequent with NALIRIFOX, including febrile neutropenia, neutropenia, thrombocytopenia, and peripheral neuropathy; however, most were transient and manageable.
CONCLUSION: NALIRIFOX provides superior PFS compared to nal-IRI/FL as second-line therapy for advanced or metastatic pancreatic cancer after gemcitabine failure. Although NALIRIFOX was associated with higher rates of hematologic and neurologic toxicities, they were manageable with careful monitoring.
OBJECTIVES: We aimed to compare the clinical outcomes and safety profiles of NALIRIFOX and nal-IRI/FL when used as a second-line treatment for patients with pancreatic adenocarcinoma who have progressed on a gemcitabine-based therapy.
DESIGNS: This was a single-center retrospective cohort study.
METHODS: We included patients with locally advanced or metastatic pancreatic adenocarcinoma who received NALIRIFOX or nal-IRI/FL following progression on first-line gemcitabine-based therapy from September 2020 to October 2024.
RESULTS: A total of 62 patients in the NALIRIFOX group and 131 in the nal-IRI/FL group were analyzed. Cumulative dose intensity ⩾80% over four cycles was achieved in 81.4% of the NALIRIFOX group and 73.1% of the nal-IRI/FL group (p = 0.32). The median progression-free survival (PFS) was 4.0 months (95% confidence interval (CI): 3.6-4.5) in the NALIRIFOX group versus 2.5 months (95% CI: 2.1-3.0) in the nal-IRI/FL group (hazard ratio (HR): 0.686; 95% CI: 0.497-0.947; p = 0.021), and the median overall survival was 7.0 months (95% CI: 5.0-9.1) versus 6.3 months (95% CI: 4.4-8.1), respectively (p = 0.827). Of the patients with disease progression after nal-IRI/FL, 69.1% received oxaliplatin-containing chemotherapy. Grade 3-4 adverse events were more frequent with NALIRIFOX, including febrile neutropenia, neutropenia, thrombocytopenia, and peripheral neuropathy; however, most were transient and manageable.
CONCLUSION: NALIRIFOX provides superior PFS compared to nal-IRI/FL as second-line therapy for advanced or metastatic pancreatic cancer after gemcitabine failure. Although NALIRIFOX was associated with higher rates of hematologic and neurologic toxicities, they were manageable with careful monitoring.